Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 50%

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.